21-hydroxylase deficiency: Difference between revisions
No edit summary |
No edit summary |
||
Line 7: | Line 7: | ||
{{CMG}}; {{AE}} {{MJ}} | {{CMG}}; {{AE}} {{MJ}} | ||
{{SK}} | {{SK}} Congenital adrenal hyperplasia due to 21-hydroxylase deficiency; 21-hydroxylase deficient congenital adrenal hyperplasia; CAH1; CYP21A deficiency; Congenital adrenal hyperplasia 1 | ||
==[[21-hydroxylase deficiency overview|Overview]]== | ==[[21-hydroxylase deficiency overview|Overview]]== | ||
Revision as of 14:53, 26 July 2017
For patient information click here
21-hydroxylase deficiency Microchapters |
Differentiating 21-Hydroxylase Deficiency from other Diseases |
Diagnosis |
Treatment |
Case Studies |
21-hydroxylase deficiency On the Web |
American Roentgen Ray Society Images of 21-hydroxylase deficiency |
Risk calculators and risk factors for 21-hydroxylase deficiency |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mehrian Jafarizade, M.D [2]
Synonyms and keywords: Congenital adrenal hyperplasia due to 21-hydroxylase deficiency; 21-hydroxylase deficient congenital adrenal hyperplasia; CAH1; CYP21A deficiency; Congenital adrenal hyperplasia 1
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating 21-Hydroxylase Deficiency from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms | Physical Examination | Laboratory Findings | Electrocardiogram | CT | MRI | Ultrasound | Other Imaging Findings | Other Diagnostic Studies
Treatment
Medical Therapy | Surgery | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies
Case Studies
Related Chapters